Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron and Tamsulosin for Ureteral Stent Symptoms
NCT06124066Phase 4Completed
- Sponsor
- Hasanuddin University
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mirabegron in ureteral stent-related symptoms (USRS), sponsored by Hasanuddin University. Primary endpoint: Interleukin-6 at 6 weeks. Started Jul 2022; status: completed.
02
Drugs
mirabegron
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on NCT06124066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124066.